5α-reductase-IN-1 is a potent inhibitor of the enzyme 5α-reductase. This compound is primarily employed in research studies to investigate its potential efficacy in treating patterned alopecia. It is commonly used in combination with minoxidil, a well-known treatment for hair loss.
JXL069 是一种最初由加州大学洛杉矶分校(University of California, Los Angeles,UCLA)开发的实验性药物,其作为一种高效且高度选择性的线粒体丙酮酸转运载体(mitochondrial pyruvate carrier,MPC)抑制剂,可有效阻断丙酮酸向线粒体内的受控转运过程,从而重塑细胞能量代谢状态。该化合物在动物模型研究中通过明确的作用机制验证,显示出作为代谢调节剂在雄激素性脱发治疗领域中的潜在应用价值和良好的临床前研究前景。
(Rac)-PF-998425 is a potent, selective, nonsteroidal antagonist of the androgen receptor (AR), with IC50 values of 26 nM and 90 nM in AR binding and cellular assays, respectively. This compound shows promise for investigating androgenetic alopecia.
5-Androstenetriol, a steroid and active metabolite of dehydroepiandrosterone (DHEA), demonstrates significant therapeutic effects. Administered at 0.75 mg/25 g body weight, it mitigates radiation-induced mortality and facilitates hematopoietic recovery from surviving stem cells in mice. Moreover, a dosage of 40 mg/kg enhances survival rates in rats subjected to surgical trauma-induced sepsis. Additionally, elevated urinary levels of 5-androstenetriol are observed in women suffering from androgenic alopecia.